Bioinformatics

Bioinformatics

NorthStrive and Yuva Biosciences validate four ANT1-inducing compounds

Four AI-selected small molecules increased ANT1 expression in human skeletal muscle cells, advancing NorthStrive's muscle-preservation programme toward confirmatory
Four AI-selected small molecules increased ANT1 expression in human skeletal muscle cells, advancing NorthStrive's muscle-preservation programme toward confirmatory
The Biotech Times Editorial Team  · 
Bioinformatics
Biologics

Corten Capital and Ampersand acquire Beacon Intelligence in PE buyout

The deal separates Beacon from the Hanson Wade Group, giving the R&D intelligence platform independent status backed by Corten's €680m second fund.
The deal separates Beacon from the Hanson Wade Group, giving the R&D intelligence platform independent status backed by Corten's €680m second fund.
The Biotech Times Editorial Team  · 
Genomics
Diagnostics
Bioinformatics

Bionano OGM studies at ESHG 2026 surge 67% year-on-year

Thirty-five studies featuring optical genome mapping appeared at ESHG 2026, up from 21 the prior year, spanning authors across 17 countries.
Thirty-five studies featuring optical genome mapping appeared at ESHG 2026, up from 21 the prior year, spanning authors across 17 countries.
The Biotech Times Editorial Team  · 
Diagnostics
Bioinformatics

Adaptive Biotechnologies plans to spin out Immune Medicine unit

The Seattle biotech will separate its profitable clonoSEQ MRD diagnostics arm from its AI-driven immune medicine discovery platform by end of 2026.
The Seattle biotech will separate its profitable clonoSEQ MRD diagnostics arm from its AI-driven immune medicine discovery platform by end of 2026.
The Biotech Times Editorial Team  · 
Bioinformatics

Nurix BTK degrader bexobrutideg shows 92.9% ORR in second-line CLL

Updated Phase 1a/b data presented at EHA 2026 show durable responses and a clean safety profile across heavily pretreated CLL patients.
Updated Phase 1a/b data presented at EHA 2026 show durable responses and a clean safety profile across heavily pretreated CLL patients.
The Biotech Times Editorial Team  · 
Bioinformatics

Syndax SAVE trial data published in JCO showing 88% ORR

Phase 1/2 SAVE data show revumenib plus decitabine/cedazuridine and venetoclax achieved 88% ORR in heavily pretreated AML patients.
Phase 1/2 SAVE data show revumenib plus decitabine/cedazuridine and venetoclax achieved 88% ORR in heavily pretreated AML patients.
The Biotech Times Editorial Team  · 
Bioinformatics
Diagnostics
Digital Health

Alzai Health files IPO prospectus on TSXV to raise up to C$4m

The Toronto-based AI Alzheimer's screening company plans to list on the TSX Venture Exchange in May, raising up to C$4 million at
The Toronto-based AI Alzheimer's screening company plans to list on the TSX Venture Exchange in May, raising up to C$4 million at
The Biotech Times Editorial Team  · 
Bioinformatics
Diagnostics

Pathos AI acquires majority stake in DeuterOncology's MET inhibitor

Pathos AI used its Foundry AI platform to identify and acquire Belgium-based DeuterOncology, whose DO-2 candidate showed 100% tumour shrinkage in a small
Pathos AI used its Foundry AI platform to identify and acquire Belgium-based DeuterOncology, whose DO-2 candidate showed 100% tumour shrinkage in a small
The Biotech Times Editorial Team  · 
Subscribe to Bioinformatics